For the first time since 1952, publication of the CDC's MMWR was halted for two week. On February 6, there were two new MMWR studies but nothing on the H5N1 bird flu.
DALLAS - Mangoceuticals, Inc. (NASDAQ: MGRX), a telemedicine company focused on men's wellness products with a market capitalization of $8.12 million, has announced progress in its H1N1 efficacy study ...
Some results have been hidden because they may be inaccessible to you